05
Medicinal compounds containing cannabis, cannabis
derivatives, natural cannabinoids, or synthetic
cannabinoids; medicinal compounds containing cannabis,
cannabis derivatives, natural cannabinoids, or synthetic
cannabinoids for treating headaches, neurodegeneration,
neurogenesis, epilepsy, childhood epilepsy, paediatric
encephalopathies, pain, cancer, managing the effects of
chemotherapy, Tourette Syndrome, post-traumatic stress
disorder (PTSD), nausea, vomiting, premenstrual syndrome
(PMS), neurologic conditions, sleep disorders, cognitive
decline, facial pain, spasms, gastrointestinal diseases,
rare diseases, Alzheimer's disease, appetite loss, cancer,
Crohn's disease, anorexia, bulimia, epilepsy, glaucoma,
schizophrenia, multiple sclerosis, muscle spasms, nausea,
pain, headaches, wasting syndrome (cachexia), and diseases
classified as "orphan" by the US Food and Drug
Administration, namely, medicinal compounds containing
cannabis, cannabis derivatives, natural cannabinoids, or
synthetic cannabinoids for treating diseases and medical
conditions classified as "orphan" by the US food and drug
administration, namely, Lennox-Gastaut Syndrome, Dravet
Syndrome, CDKL5, 15q Duplication Syndrome, KCNQ2 related
epileptic encephalopathy, SCN8A related epileptic
encephalopathy, Electrical status epilepticus in sleep
(ESES), Landau-Kleffner syndrome, Continuous spikes and
waves during sleep, Tuberous sclerosis complex, Doose
Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome,
SYNGAP related epileptic encephalopathy, Fragile X Syndrome,
epilepsy with focal cortical dysplasia type II, KCNT1
related epileptic encephalopathy, SCN2A related epileptic
encephalopathy, STXBP1 related epileptic encephalopathy,
KAND KIF1A related epileptic encephalopathy, HNRNPH2 related
epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3,
Angelman Syndrome, Established Status Epilepticus,
Refractory Status Epilepticus, Juvenile Myoclonic
Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant
mesial temporal lobe epilepsy, Occipital Lobe epilepsy,
Jeavons syndrome, Benign Rolandic epilepsy or benign
childhood epilepsy with centrotemporal spikes (BCECTS),
Epilepsy with myoclonic absences, Childhood absence epilepsy
(CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC),
Panayiotopoulos syndrome, Benign Occipital Epilepsy,
Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G),
Benign myoclonic epilepsy in infancy, Myoclonic astatic
epilepsy (MAE), Cornelia de Lange Syndrome (CdLS),
Convulsive Seizures, TBI Seizures, Focal Seizures,
Generalized onset Seizures, Progressive Myoclonic Epilepsy,
Reflex Epilepsy, Abdominal Epilepsy, Photosensitive
Epilepsy, Refractory Epilepsy, Automatism Epilepsy,
Catamenial epilepsy, Epilepsia partialis continua, Febrile
infection-related epilepsy syndrome (FIRES), Migralepsy,
Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy,
Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy
(PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg
disease (abbreviated ULD or EPM1), Vertiginous epilepsy;
Medicinal herbal extracts for treating disease; Medicinal
herbal extracts for treating headaches, neurodegeneration,
neurogenesis, epilepsy, childhood epilepsy, paediatric
encephalopathies, pain, cancer, managing the effects of
chemotherapy, Tourette Syndrome, post-traumatic stress
disorder (PTSD), nausea, vomiting, premenstrual syndrome
(PMS), neurologic conditions, sleep disorders, cognitive
decline, facial pain, spasms, gastrointestinal diseases,
rare diseases, Alzheimer's disease, appetite loss, cancer,
Crohn's disease, anorexia, bulimia, epilepsy, glaucoma,
schizophrenia, multiple sclerosis, muscle spasms, nausea,
pain, headaches, wasting syndrome (cachexia), and diseases
classified as "orphan" by the US Food and Drug
Administration, namely, medical cannabis and marijuana
extracts for treating diseases and medical conditions
classified as "orphan" by the US food and drug
administration, namely, Lennox-Gastaut Syndrome, Dravet
Syndrome, CDKL5,15q Duplication Syndrome, KCNQ2 related
epileptic encephalopathy, SCN8A related epileptic
encephalopathy, Electrical status epilepticus in sleep
(ESES), Landau-Kleffner syndrome, Continuous spikes and
waves during sleep, Tuberous sclerosis complex, Doose
Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome,
SYNGAP related epileptic encephalopathy, Fragile X Syndrome,
epilepsy with focal cortical dysplasia type II, KCNT1
related epileptic encephalopathy, SCN2A related epileptic
encephalopathy, STXBP1 related epileptic encephalopathy,
KAND KIF1A related epileptic encephalopathy, HNRNPH2 related
epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3,
Angelman Syndrome, Established Status Epilepticus,
Refractory Status Epilepticus, Juvenile Myoclonic
Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant
mesial temporal lobe epilepsy, Occipital Lobe epilepsy,
Jeavons syndrome, Benign Rolandic epilepsy or benign
childhood epilepsy with centrotemporal spikes (BCECTS),
Epilepsy with myoclonic absences, Childhood absence epilepsy
(CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC),
Panayiotopoulos syndrome, Benign Occipital Epilepsy,
Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G),
Benign myoclonic epilepsy in infancy, Myoclonic astatic
epilepsy (MAE), Cornelia de Lange Syndrome (CdLS),
Convulsive Seizures, TBI Seizures, Focal Seizures,
Generalized onset Seizures, Progressive Myoclonic Epilepsy,
Reflex Epilepsy, Abdominal Epilepsy, Photosensitive
Epilepsy, Refractory Epilepsy, Automatism Epilepsy,
Catamenial epilepsy, Epilepsia partialis continua, Febrile
infection-related epilepsy syndrome (FIRES), Migralepsy,
Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy,
Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy
(PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg
disease (abbreviated ULD or EPM1), Vertiginous epilepsy;
medicinal herbal preparations; medicinal herbal preparations
for treating headaches, neurodegeneration, neurogenesis,
epilepsy, childhood epilepsy, paediatric encephalopathies,
pain, cancer, managing the effects of chemotherapy, Tourette
Syndrome, post-traumatic stress disorder (PTSD), nausea,
vomiting, premenstrual syndrome (PMS), neurologic
conditions, sleep disorders, cognitive decline, facial pain,
spasms, gastrointestinal diseases, rare diseases,
Alzheimer's disease, appetite loss, cancer, Crohn's disease,
anorexia, bulimia, epilepsy, glaucoma, schizophrenia,
multiple sclerosis, muscle spasms, nausea, pain, headaches,
wasting syndrome (cachexia), and diseases classified as
"orphan" by the US Food and Drug Administration, namely
marijuana preparations, cannabis dried flowers and
concentrates for treating diseases and medical conditions
classified as "orphan" by the US food and drug
administration, namely, Lennox-Gastaut Syndrome, Dravet
Syndrome, CDKL5, 15q Duplication Syndrome, KCNQ2 related
epileptic encephalopathy, SCN8A related epileptic
encephalopathy, Electrical status epilepticus in sleep
(ESES), Landau-Kleffner syndrome, Continuous spikes and
waves during sleep, Tuberous sclerosis complex, Doose
Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome,
SYNGAP related epileptic encephalopathy, Fragile X Syndrome,
epilepsy with focal cortical dysplasia type II, KCNT1
related epileptic encephalopathy, SCN2A related epileptic
encephalopathy, STXBP1 related epileptic encephalopathy,
KAND KIF1A related epileptic encephalopathy, HNRNPH2 related
epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3,
Angelman Syndrome, Established Status Epilepticus,
Refractory Status Epilepticus, Juvenile Myoclonic
Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant
mesial temporal lobe epilepsy, Occipital Lobe epilepsy,
Jeavons syndrome, Benign Rolandic epilepsy or benign
childhood epilepsy with centrotemporal spikes (BCECTS),
Epilepsy with myoclonic absences, Childhood absence epilepsy
(CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC),
Panayiotopoulos syndrome, Benign Occipital Epilepsy,
Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G),
Benign myoclonic epilepsy in infancy, Myoclonic astatic
epilepsy (MAE), Cornelia de Lange Syndrome (CdLS),
Convulsive Seizures, TBI Seizures, Focal Seizures,
Generalized onset Seizures, Progressive Myoclonic Epilepsy,
Reflex Epilepsy, Abdominal Epilepsy, Photosensitive
Epilepsy, Refractory Epilepsy, Automatism Epilepsy,
Catamenial epilepsy, Epilepsia partialis continua, Febrile
infection-related epilepsy syndrome (FIRES), Migralepsy,
Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy,
Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy
(PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg
disease (abbreviated ULD or EPM1), Vertiginous epilepsy;
Marijuana derivatives, natural cannabinoids, and synthetic
cannabinoids used for treating medical conditions; Marijuana
derivatives, natural cannabinoids, and synthetic
cannabinoids used for treating headaches, neurodegeneration,
neurogenesis, epilepsy, childhood epilepsy, paediatric
encephalopathies, pain, cancer, managing the effects of
chemotherapy, Tourette Syndrome, post-traumatic stress
disorder (PTSD), nausea, vomiting, premenstrual syndrome
(PMS), neurologic conditions, sleep disorders, cognitive
decline, facial pain, spasms, gastrointestinal diseases,
rare diseases, Alzheimer's disease, appetite loss, cancer,
managing the effects of chemotherapy, Crohn's disease,
anorexia, bulimia, epilepsy, glaucoma, schizophrenia,
multiple sclerosis, muscle spasms, nausea, pain, headaches,
wasting syndrome (cachexia), and diseases classified as
"orphan" by the US Food and Drug Administration, namely
liquids, oils, oral sprays, pills, capsules, creams,
tinctures, lotions, suppositories, and baked medicinal goods
for treating diseases and medical conditions classified as
"orphan" by the US food and drug administration, namely,
Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q
Duplication Syndrome, KCNQ2 related epileptic
encephalopathy, SCN8A related epileptic encephalopathy,
Electrical status epilepticus in sleep (ESES),
Landau-Kleffner syndrome, Continuous spikes and waves during
sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara
Syndrome, Rett Syndrome, West Syndrome, SYNGAP related
epileptic encephalopathy, Fragile X Syndrome, epilepsy with
focal cortical dysplasia type II, KCNT1 related epileptic
encephalopathy, SCN2A related epileptic encephalopathy,
STXBP1 related epileptic encephalopathy, KAND KIF1A related
epileptic encephalopathy, HNRNPH2 related epileptic
encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman
Syndrome, Established Status Epilepticus, Refractory Status
Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome,
Catamenial epilepsy, Drug resistant mesial temporal lobe
epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign
Rolandic epilepsy or benign childhood epilepsy with
centrotemporal spikes (BCECTS), Epilepsy with myoclonic
absences, Childhood absence epilepsy (CAE), Tuberous
Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos
syndrome, Benign Occipital Epilepsy, Idiopathic childhood
occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic
epilepsy in infancy, Myoclonic astatic epilepsy (MAE),
Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI
Seizures, Focal Seizures, Generalized onset Seizures,
Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal
Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy,
Automatism Epilepsy, Catamenial epilepsy, Epilepsia
partialis continua, Febrile infection-related epilepsy
syndrome (FIRES), Migralepsy, Musicogenic epilepsy,
Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy,
Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy
(TLE), Unverricht-Lundborg disease (abbreviated ULD or
EPM1), Vertiginous epilepsy; medicinal herbs for treating
headaches, neurodegeneration, neurogenesis, epilepsy,
childhood epilepsy, paediatric encephalopathies, pain,
cancer, managing the effects of chemotherapy, Tourette
Syndrome, post-traumatic stress disorder (PTSD), nausea,
vomiting, premenstrual syndrome (PMS), neurologic
conditions, sleep disorders, cognitive decline, facial pain,
spasms, gastrointestinal diseases, rare diseases,
Alzheimer's disease, appetite loss, cancer, Crohn's disease,
anorexia, bulimia, epilepsy, glaucoma, schizophrenia,
multiple sclerosis, muscle spasms, nausea, pain, headaches,
wasting syndrome (cachexia), and diseases classified as
"orphan" by the US Food and Drug Administration, namely
Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q
Duplication Syndrome, KCNQ2 related epileptic
encephalopathy, SCN8A related epileptic encephalopathy,
Electrical status epilepticus in sleep (ESES),
Landau-Kleffner syndrome, Continuous spikes and waves during
sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara
Syndrome, Rett Syndrome, West Syndrome, SYNGAP related
epileptic encephalopathy, Fragile X Syndrome, epilepsy with
focal cortical dysplasia type II, KCNT1 related epileptic
encephalopathy, SCN2A related epileptic encephalopathy,
STXBP1 related epileptic encephalopathy, KAND KIF1A related
epileptic encephalopathy, HNRNPH2 related epileptic
encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman
Syndrome, Established Status Epilepticus, Refractory Status
Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome,
Catamenial epilepsy, Drug resistant mesial temporal lobe
epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign
Rolandic epilepsy or benign childhood epilepsy with
centrotemporal spikes (BCECTS), Epilepsy with myoclonic
absences, Childhood absence epilepsy (CAE), Tuberous
Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos
syndrome, Benign Occipital Epilepsy, Idiopathic childhood
occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic
epilepsy in infancy, Myoclonic astatic epilepsy (MAE),
Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI
Seizures, Focal Seizures, Generalized onset Seizures,
Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal
Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy,
Automatism Epilepsy, Catamenial epilepsy, Epilepsia
partialis continua, Febrile infection-related epilepsy
syndrome (FIRES), Migralepsy, Musicogenic epilepsy,
Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy,
Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy
(TLE), Unverricht-Lundborg disease (abbreviated ULD or
EPM1), Vertiginous epilepsy; medicinal herbs in dried or
preserved form for treating headaches, neurodegeneration,
neurogenesis, epilepsy, childhood epilepsy, paediatric
encephalopathies, pain, cancer, managing the effects of
chemotherapy, Tourette Syndrome, post-traumatic stress
disorder (PTSD), nausea, vomiting, premenstrual syndrome
(PMS), neurologic conditions, sleep disorders, cognitive
decline, facial pain, spasms, gastrointestinal diseases,
rare diseases, Alzheimer's disease, appetite loss, cancer,
Crohn's disease, anorexia, bulimia, epilepsy, glaucoma,
schizophrenia, multiple sclerosis, muscle spasms, nausea,
pain, headaches, wasting syndrome (cachexia), and diseases
classified as "orphan" by the US Food and Drug
Administration, namely medical marijuana and cannabis for
treating diseases and medical conditions classified as
"orphan" by the US food and drug administration, namely,
Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q
Duplication Syndrome, KCNQ2 related epileptic
encephalopathy, SCN8A related epileptic encephalopathy,
Electrical status epilepticus in sleep (ESES),
Landau-Kleffner syndrome, Continuous spikes and waves during
sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara
Syndrome, Rett Syndrome, West Syndrome, SYNGAP related
epileptic encephalopathy, Fragile X Syndrome, epilepsy with
focal cortical dysplasia type II, KCNT1 related epileptic
encephalopathy, SCN2A related epileptic encephalopathy,
STXBP1 related epileptic encephalopathy, KAND KIF1A related
epileptic encephalopathy, HNRNPH2 related epileptic
encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman
Syndrome, Established Status Epilepticus, Refractory Status
Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome,
Catamenial epilepsy, Drug resistant mesial temporal lobe
epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign
Rolandic epilepsy or benign childhood epilepsy with
centrotemporal spikes (BCECTS), Epilepsy with myoclonic
absences, Childhood absence epilepsy (CAE), Tuberous
Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos
syndrome, Benign Occipital Epilepsy, Idiopathic childhood
occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic
epilepsy in infancy, Myoclonic astatic epilepsy (MAE),
Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI
Seizures, Focal Seizures, Generalized onset Seizures,
Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal
Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy,
Automatism Epilepsy, Catamenial epilepsy, Epilepsia
partialis continua, Febrile infection-related epilepsy
syndrome (FIRES), Migralepsy, Musicogenic epilepsy,
Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy,
Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy
(TLE), Unverricht-Lundborg disease (abbreviated ULD or
EPM1), Vertiginous epilepsy; pills, capsules, infused with
cannabis, medical marijuana, natural cannabinoids, or
synthetic cannabinoids; extracts and derivatives of
cannabis, medical marijuana, natural cannabinoids, and
synthetic cannabinoids for treating headaches,
neurodegeneration, neurogenesis, epilepsy, childhood
epilepsy, paediatric encephalopathies, pain, cancer,
managing the effects of chemotherapy, Tourette Syndrome,
post-traumatic stress disorder (PTSD), nausea, vomiting,
premenstrual syndrome (PMS), neurologic conditions, sleep
disorders, cognitive decline, facial pain, spasms,
gastrointestinal diseases, rare diseases, Alzheimer's
disease, appetite loss, cancer, Crohn's disease, anorexia,
bulimia, epilepsy, glaucoma, schizophrenia, multiple
sclerosis, muscle spasms, nausea, pain, headaches, wasting
syndrome (cachexia), and diseases classified as "orphan" by
the US Food and Drug Administration, namely, salves,
concentrates, pastes, extracts, tinctures, marijuana clones,
cannabis clones, tissue cultures, powders, juice, resins,
oils, and tetrahydrocannabinol (THC) for treating diseases
and medical conditions classified as "orphan" by the US food
and drug administration, namely, Lennox-Gastaut Syndrome,
Dravet Syndrome, CDKL5,15q Duplication Syndrome, KCNQ2
related epileptic encephalopathy, SCN8A related epileptic
encephalopathy, Electrical status epilepticus in sleep
(ESES), Landau-Kleffner syndrome, Continuous spikes and
waves during sleep, Tuberous sclerosis complex, Doose
Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome,
SYNGAP related epileptic encephalopathy, Fragile X Syndrome,
epilepsy with focal cortical dysplasia type II, KCNT1
related epileptic encephalopathy, SCN2A related epileptic
encephalopathy, STXBP1 related epileptic encephalopathy,
KAND KIF1A related epileptic encephalopathy, HNRNPH2 related
epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3,
Angelman Syndrome, Established Status Epilepticus,
Refractory Status Epilepticus, Juvenile Myoclonic
Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant
mesial temporal lobe epilepsy, Occipital Lobe epilepsy,
Jeavons syndrome, Benign Rolandic epilepsy or benign
childhood epilepsy with centrotemporal spikes (BCECTS),
Epilepsy with myoclonic absences, Childhood absence epilepsy
(CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC),
Panayiotopoulos syndrome, Benign Occipital Epilepsy,
Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G),
Benign myoclonic epilepsy in infancy, Myoclonic astatic
epilepsy (MAE), Cornelia de Lange Syndrome (CdLS),
Convulsive Seizures, TBI Seizures, Focal Seizures,
Generalized onset Seizures, Progressive Myoclonic Epilepsy,
Reflex Epilepsy, Abdominal Epilepsy, Photosensitive
Epilepsy, Refractory Epilepsy, Automatism Epilepsy,
Catamenial epilepsy, Epilepsia partialis continua, Febrile
infection-related epilepsy syndrome (FIRES), Migralepsy,
Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy,
Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy
(PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg
disease (abbreviated ULD or EPM1), Vertiginous epilepsy;
suppositories infused with cannabis, medical marijuana,
natural cannabinoids, cannabis derivatives, or synthetic
cannabinoids; Suppositories infused with cannabis, medical
marijuana, cannabis derivatives, natural cannabinoids, or
synthetic cannabinoids for treating headaches,
neurodegeneration, neurogenesis, epilepsy, childhood
epilepsy, paediatric encephalopathies, pain, cancer,
managing the effects of chemotherapy, Tourette Syndrome,
post-traumatic stress disorder (PTSD), nausea, vomiting,
premenstrual syndrome (PMS), neurologic conditions, sleep
disorders, cognitive decline, facial pain, spasms,
gastrointestinal diseases, rare diseases, Alzheimer's
disease, appetite loss, cancer, Crohn's disease, anorexia,
bulimia, epilepsy, glaucoma, schizophrenia, multiple
sclerosis, muscle spasms, nausea, pain, headaches, wasting
syndrome (cachexia), and diseases classified as "orphan" by
the US Food and Drug Administration, namely, Lennox-Gastaut
Syndrome, Dravet Syndrome, CDKL5,15q Duplication Syndrome,
KCNQ2 related epileptic encephalopathy, SCN8A related
epileptic encephalopathy, Electrical status epilepticus in
sleep (ESES), Landau-Kleffner syndrome, Continuous spikes
and waves during sleep, Tuberous sclerosis complex, Doose
Syndrome, Otahara Syndrome, Rett Syndrome, West Syndrome,
SYNGAP related epileptic encephalopathy, Fragile X Syndrome,
epilepsy with focal cortical dysplasia type II, KCNT1
related epileptic encephalopathy, SCN2A related epileptic
encephalopathy, STXBP1 related epileptic encephalopathy,
KAND KIF1A related epileptic encephalopathy, HNRNPH2 related
epileptic encephalopathy, Phelan-McDermid Syndrome - SHANK3,
Angelman Syndrome, Established Status Epilepticus,
Refractory Status Epilepticus, Juvenile Myoclonic
Epilepsy/Janz Syndrome, Catamenial epilepsy, Drug resistant
mesial temporal lobe epilepsy, Occipital Lobe epilepsy,
Jeavons syndrome, Benign Rolandic epilepsy or benign
childhood epilepsy with centrotemporal spikes (BCECTS),
Epilepsy with myoclonic absences, Childhood absence epilepsy
(CAE), Tuberous Sclerosis/Tuberous Sclerosis Complex (TSC),
Panayiotopoulos syndrome, Benign Occipital Epilepsy,
Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G),
Benign myoclonic epilepsy in infancy, Myoclonic astatic
epilepsy (MAE), Cornelia de Lange Syndrome (CdLS),
Convulsive Seizures, TBI Seizures, Focal Seizures,
Generalized onset Seizures, Progressive Myoclonic Epilepsy,
Reflex Epilepsy, Abdominal Epilepsy, Photosensitive
Epilepsy, Refractory Epilepsy, Automatism Epilepsy,
Catamenial epilepsy, Epilepsia partialis continua, Febrile
infection-related epilepsy syndrome (FIRES), Migralepsy,
Musicogenic epilepsy, Nocturnal Frontal Lobe epilepsy,
Occipital Lobe epilepsy, Post-traumatic (TBI) epilepsy
(PTE), Temporal lobe epilepsy (TLE), Unverricht-Lundborg
disease (abbreviated ULD or EPM1), Vertiginous epilepsy;
transdermal patches infused with cannabis, medical
marijuana, marijuana plant derivatives, natural
cannabinoids, or synthetic cannabinoids; Transdermal patches
infused with cannabis, medical marijuana, marijuana plant
derivatives, natural cannabinoids, or synthetic cannabinoids
for treating headaches, neurodegeneration, neurogenesis,
epilepsy, childhood epilepsy, paediatric encephalopathies,
pain, cancer, managing the effects of chemotherapy, Tourette
Syndrome, post-traumatic stress disorder (PTSD), nausea,
vomiting, premenstrual syndrome (PMS), neurologic
conditions, sleep disorders, cognitive decline, facial pain,
spasms, gastrointestinal diseases, rare diseases,
Alzheimer's disease, appetite loss, cancer, Crohn's disease,
anorexia, bulimia, epilepsy, glaucoma, schizophrenia,
multiple sclerosis, muscle spasms, nausea, pain, headaches,
wasting syndrome (cachexia), and diseases classified as
"orphan" by the US Food and Drug Administration, namely,
Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q
Duplication Syndrome, KCNQ2 related epileptic
encephalopathy, SCN8A related epileptic encephalopathy,
Electrical status epilepticus in sleep (ESES),
Landau-Kleffner syndrome, Continuous spikes and waves during
sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara
Syndrome, Rett Syndrome, West Syndrome, SYNGAP related
epileptic encephalopathy, Fragile X Syndrome, epilepsy with
focal cortical dysplasia type II, KCNT1 related epileptic
encephalopathy, SCN2A related epileptic encephalopathy,
STXBP1 related epileptic encephalopathy, KAND KIF1A related
epileptic encephalopathy, HNRNPH2 related epileptic
encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman
Syndrome, Established Status Epilepticus, Refractory Status
Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome,
Catamenial epilepsy, Drug resistant mesial temporal lobe
epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign
Rolandic epilepsy or benign childhood epilepsy with
centrotemporal spikes (BCECTS), Epilepsy with myoclonic
absences, Childhood absence epilepsy (CAE), Tuberous
Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos
syndrome, Benign Occipital Epilepsy, Idiopathic childhood
occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic
epilepsy in infancy, Myoclonic astatic epilepsy (MAE),
Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI
Seizures, Focal Seizures, Generalized onset Seizures,
Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal
Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy,
Automatism Epilepsy, Catamenial epilepsy, Epilepsia
partialis continua, Febrile infection-related epilepsy
syndrome (FIRES), Migralepsy, Musicogenic epilepsy,
Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy,
Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy
(TLE), Unverricht-Lundborg disease (abbreviated ULD or
EPM1), Vertiginous epilepsy; Cannabis, cannabinoids, and
medical marijuana based petfoods and medications; Cannabis,
cannabinoids, and medical marijuana based pet foods and
medications for treating pets for veterinary conditions;
edible oils and edible butters containing cannabis, medical
marijuana, marijuana plant derivatives, natural
cannabinoids, or synthetic cannabinoids; Edible oils and
edible butters containing cannabis, medical marijuana plant
derivatives, natural cannabinoids, or synthetic cannabinoids
for treating headaches, neurodegeneration, neurogenesis,
epilepsy, childhood epilepsy, paediatric encephalopathies,
pain, cancer, managing the effects of chemotherapy, Tourette
Syndrome, post-traumatic stress disorder (PTSD), nausea,
vomiting, premenstrual syndrome (PMS), neurologic
conditions, sleep disorders, cognitive decline, facial pain,
spasms, gastrointestinal diseases, rare diseases,
Alzheimer's disease, appetite loss, cancer, Crohn's disease,
anorexia, bulimia, epilepsy, glaucoma, schizophrenia,
multiple sclerosis, muscle spasms, nausea, pain, headaches,
wasting syndrome (cachexia), and diseases classified as
"orphan" by the US Food and Drug Administration, namely,
Lennox-Gastaut Syndrome, Dravet Syndrome, CDKL5,15q
Duplication Syndrome, KCNQ2 related epileptic
encephalopathy, SCN8A related epileptic encephalopathy,
Electrical status epilepticus in sleep (ESES),
Landau-Kleffner syndrome, Continuous spikes and waves during
sleep, Tuberous sclerosis complex, Doose Syndrome, Otahara
Syndrome, Rett Syndrome, West Syndrome, SYNGAP related
epileptic encephalopathy, Fragile X Syndrome, epilepsy with
focal cortical dysplasia type II, KCNT1 related epileptic
encephalopathy, SCN2A related epileptic encephalopathy,
STXBP1 related epileptic encephalopathy, KAND KIF1A related
epileptic encephalopathy, HNRNPH2 related epileptic
encephalopathy, Phelan-McDermid Syndrome - SHANK3, Angelman
Syndrome, Established Status Epilepticus, Refractory Status
Epilepticus, Juvenile Myoclonic Epilepsy/Janz Syndrome,
Catamenial epilepsy, Drug resistant mesial temporal lobe
epilepsy, Occipital Lobe epilepsy, Jeavons syndrome, Benign
Rolandic epilepsy or benign childhood epilepsy with
centrotemporal spikes (BCECTS), Epilepsy with myoclonic
absences, Childhood absence epilepsy (CAE), Tuberous
Sclerosis/Tuberous Sclerosis Complex (TSC), Panayiotopoulos
syndrome, Benign Occipital Epilepsy, Idiopathic childhood
occipital epilepsy of Gastaut (ICOE-G), Benign myoclonic
epilepsy in infancy, Myoclonic astatic epilepsy (MAE),
Cornelia de Lange Syndrome (CdLS), Convulsive Seizures, TBI
Seizures, Focal Seizures, Generalized onset Seizures,
Progressive Myoclonic Epilepsy, Reflex Epilepsy, Abdominal
Epilepsy, Photosensitive Epilepsy, Refractory Epilepsy,
Automatism Epilepsy, Catamenial epilepsy, Epilepsia
partialis continua, Febrile infection-related epilepsy
syndrome (FIRES), Migralepsy, Musicogenic epilepsy,
Nocturnal Frontal Lobe epilepsy, Occipital Lobe epilepsy,
Post-traumatic (TBI) epilepsy (PTE), Temporal lobe epilepsy
(TLE), Unverricht-Lundborg disease (abbreviated ULD or
EPM1), Vertiginous epilepsy; Cannabis, medical marijuana,
marijuana plant derivatives, natural cannabinoids, or
synthetic cannabinoids - infused foods for medical purposes,
namely, frozen foods, treats, desserts, baked goods,
desserts, grain based bars, cakes, cereal bars, cookies,
brownies, muffins, cupcakes, chocolate, chocolate
confectionery, sugar confectionery, candies, gum, jellies,
biscuits, ice cream, sorbet, and frozen bars; beverages
infused with medical cannabis, medical marijuana, medical
marijuana plant derivatives, medical natural cannabinoids,
or medical synthetic cannabinoids
35
Providing information to the public in the field of medical
cannabis and its use in the treatment of medical conditions
40
Manufacturing medical cannabis compounds to the order and
specification of others; manufacturing products that contain
medical cannabis compounds to the order and specification of
others
42
Research, development and formulation services in the field
of medical cannabis compounds to the order and specification
of others; research, development and formulation services in
the field of products that contain medical cannabis
compounds to the order and specification of others;
providing information to the public in the field of research
in the field of medical marijuana
44
Providing information to the public via an Internet website
in the field of pharmaceutical advice concerning medical
cannabis and its use in the treatment of medical conditions